Comparative Pharmacology
Head-to-head clinical analysis: AMITIZA versus LUBIPROSTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITIZA versus LUBIPROSTONE.
AMITIZA vs LUBIPROSTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitiza (lubiprostone) is a bicyclic fatty acid metabolite that activates type 2 chloride channels (ClC-2) on the apical surface of gastrointestinal epithelial cells, increasing chloride secretion into the lumen. This promotes passive sodium and water secretion, enhancing intestinal fluid accumulation and accelerating gastrointestinal transit without affecting serum electrolyte levels. It also has a potential effect on activating chloride channels in other tissues, such as the uterus and bladder.
Lubiprostone is a bicyclic fatty acid derivative that activates type 2 chloride channels (ClC-2) in the apical membrane of intestinal epithelial cells, increasing chloride secretion and resulting in increased intestinal fluid secretion and motility.
24 mcg orally twice daily with food
24 mcg orally twice daily with food.
None Documented
None Documented
Clinical Note
moderateTiaprofenic acid + Lubiprostone
"The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Tiaprofenic acid."
Clinical Note
moderateCarprofen + Lubiprostone
"The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Carprofen."
Clinical Note
moderateMesalazine + Lubiprostone
"The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mesalazine."
Clinical Note
moderateBalsalazide + Lubiprostone
Terminal elimination half-life is approximately 0.9-1.4 hours; clinical context: short half-life supports once-daily dosing in chronic constipation.
Terminal elimination half-life of active metabolite M3 is approximately 11-13 hours; parent drug half-life is very short (<1 hour). The metabolite half-life supports twice-daily dosing.
Primarily fecal (60-70%) as unchanged drug following biliary excretion; renal excretion accounts for <10%.
Primarily fecal (approximately 55-65%) via biliary secretion as active metabolite (M3); <1% unchanged drug in urine. Renal excretion is negligible.
Category C
Category C
Chloride Channel Activator
Chloride Channel Activator
"The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Balsalazide."